We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
Cap. Flow
+$192M
Cap. Flow %
7.6%
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.4M
2
ABBV icon
AbbVie
ABBV
+$31.2M
3
AGN
Allergan plc
AGN
+$24M
4
BAX icon
Baxter International
BAX
+$22.3M
5
GILD icon
Gilead Sciences
GILD
+$20.2M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$59.8M
2
AGN
Allergan Inc
AGN
+$48.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.5M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$22.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.13%
2 Real Estate 3.95%
3 Financials 1.4%
4 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
51
CALL
AbbVie
ABBV
$455B
$11.7M 0.46%
+200,000
New +$12.1M
SYK icon
52
Stryker
SYK
$133B
$11.4M 0.45%
123,940
+28,100
+29% +$2.62M
PRGO icon
53
CALL
Perrigo
PRGO
$1.43B
$11.2M 0.44%
+67,700
New +$10.8M
HCA icon
54
HCA Healthcare
HCA
$85.7B
$11.1M 0.44%
147,488
– –
CYH icon
55
Community Health Systems
CYH
$391M
$11M 0.43%
253,582
+66,429
+35% +$2.75M
LTC
56
LTC Properties
LTC
$2.06B
$10.9M 0.43%
236,618
– –
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.6M 0.42%
679,100
– –
DHC
58
Diversified Healthcare Trust
DHC
$2.17B
$10.6M 0.42%
483,920
+70,730
+17% +$1.58M
MRK icon
59
Merck
MRK
$321B
$10.6M 0.42%
+193,880
New +$11M
STJ
60
DELISTED
St Jude Medical
STJ
$10.6M 0.42%
161,510
+39,000
+32% +$2.59M
CI icon
61
Cigna
CI
$76.1B
$9.61M 0.38%
74,251
– –
SGNT
62
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$9.52M 0.38%
409,500
+324,000
+379% +$8.58M
AGIO icon
63
Agios Pharmaceuticals
AGIO
$1.95B
$9.46M 0.37%
100,300
+54,100
+117% +$6.06M
ELGX
64
DELISTED
Endologix Inc
ELGX
$9.41M 0.37%
55,100
– –
TXMD icon
65
TherapeuticsMD
TXMD
$23.5M
$8.96M 0.36%
+29,630
New +$7.23M
IDXX icon
66
Idexx Laboratories
IDXX
$44.1B
$8.69M 0.34%
112,530
– –
CNC icon
67
Centene
CNC
$30.1B
$8.48M 0.34%
240,000
– –
WCG
68
DELISTED
Wellcare Health Plans, Inc.
WCG
$8.11M 0.32%
88,652
– –
GEVA
69
CALL
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$6.92M 0.27%
+71,000
New +$7.52M
ARAY icon
70
Accuray
ARAY
$33.9M
$6.81M 0.27%
731,943
– –
MACK
71
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$6.75M 0.27%
72,166
– –
BLUE
72
DELISTED
bluebird bio
BLUE
$6.58M 0.26%
4,209
– –
INFI
73
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.13M 0.24%
438,623
– –
ALNY icon
74
CALL
Alnylam Pharmaceuticals
ALNY
$27.4B
$5.67M 0.22%
+54,300
New +$5.5M
ILMN icon
75
CALL
Illumina
ILMN
$31B
$5.46M 0.22%
+30,223
New +$5.69M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Tekla Capital Management deployed $192M of net new capital in Q1 2015, opening 32 new positions and adding to 30 existing holdings. Its largest new stake was Baxter International: 588,384 shares worth $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $28.5M trimmed.

  • Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
  • Tekla Capital Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $33.4M increase.
  • Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
  • Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
  • Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
  • Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
  • Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.

Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.